NCT03590652 - Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 17, 2018

Primary Completion Date

July 2, 2025

Study Completion Date

July 2, 2025

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG

Ixazomib

4mg PO days 1,8,15 on 28-day cycle

DRUG

Pomalidomide

4mg days PO 1-21/28 days

DRUG

Dexamethasone

"40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg"

DRUG

Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)

1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly

Trial Locations (4)

University of California, Los Angeles, Los Angeles

UCSD Moores Cancer Center, La Jolla

University of California, San Francisco, San Francisco

University of California, Davis, Sacramento